Second, we did not employ S1PR1 antagonist to confirm the relationship between S1pr1 and Mir223. S1PR1-5 antagonist (FTY720/fingolimod) is approved for multiple sclerosis (60), while selective S1PR1 antagonist (cenerimod) is currently under phase 2 clinical study (NCT-02472795) in the patients with SLE. This evidence concerns the gene S1PR1 and multiple sclerosis.